JP2016525544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525544A5 JP2016525544A5 JP2016529754A JP2016529754A JP2016525544A5 JP 2016525544 A5 JP2016525544 A5 JP 2016525544A5 JP 2016529754 A JP2016529754 A JP 2016529754A JP 2016529754 A JP2016529754 A JP 2016529754A JP 2016525544 A5 JP2016525544 A5 JP 2016525544A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- injection
- composition according
- triamcinolone
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 238000002347 injection Methods 0.000 claims 21
- 239000007924 injection Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 9
- 239000003242 anti bacterial agent Substances 0.000 claims 7
- 239000003246 corticosteroid Substances 0.000 claims 7
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 7
- 229960003702 moxifloxacin Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 229960005294 triamcinolone Drugs 0.000 claims 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 6
- WVPSKSLAZQPAKQ-SOSAQKQKSA-N trovafloxacin Chemical group C([C@H]1C([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-SOSAQKQKSA-N 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229920001992 poloxamer 407 Polymers 0.000 claims 4
- 229940044476 poloxamer 407 Drugs 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 3
- 239000004599 antimicrobial Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000003381 solubilizing effect Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 claims 1
- 108010053950 Teicoplanin Proteins 0.000 claims 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 claims 1
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 150000001241 acetals Chemical class 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 229960004648 betamethasone acetate Drugs 0.000 claims 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 1
- 210000004240 ciliary body Anatomy 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- -1 decouplerine Chemical compound 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
- 229960001048 fluorometholone Drugs 0.000 claims 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229960003548 polymyxin b sulfate Drugs 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 229950003551 ramoplanin Drugs 0.000 claims 1
- 108010076689 ramoplanin Proteins 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229960001608 teicoplanin Drugs 0.000 claims 1
- 229960005240 telavancin Drugs 0.000 claims 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 1
- 108010089019 telavancin Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229950006782 triamcinolone benetonide Drugs 0.000 claims 1
- GUYPYYARYIIWJZ-CYEPYHPTSA-N triamcinolone benetonide Chemical compound O=C([C@]12[C@H](OC(C)(C)O1)C[C@@H]1[C@@]2(C[C@H](O)[C@]2(F)[C@@]3(C)C=CC(=O)C=C3CC[C@H]21)C)COC(=O)C(C)CNC(=O)C1=CC=CC=C1 GUYPYYARYIIWJZ-CYEPYHPTSA-N 0.000 claims 1
- 229960004320 triamcinolone diacetate Drugs 0.000 claims 1
- 229960004221 triamcinolone hexacetonide Drugs 0.000 claims 1
- 229960001082 trimethoprim Drugs 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361958170P | 2013-07-22 | 2013-07-22 | |
| US61/958,170 | 2013-07-22 | ||
| PCT/US2014/032026 WO2015012899A1 (en) | 2013-07-22 | 2014-03-27 | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019108368A Division JP7232128B2 (ja) | 2013-07-22 | 2019-06-11 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525544A JP2016525544A (ja) | 2016-08-25 |
| JP2016525544A5 true JP2016525544A5 (enExample) | 2017-04-06 |
Family
ID=50640013
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529754A Pending JP2016525544A (ja) | 2013-07-22 | 2014-03-27 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2019108368A Active JP7232128B2 (ja) | 2013-07-22 | 2019-06-11 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2021083925A Pending JP2021121608A (ja) | 2013-07-22 | 2021-05-18 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2022157885A Active JP7362870B2 (ja) | 2013-07-22 | 2022-09-30 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2023172708A Pending JP2024001149A (ja) | 2013-07-22 | 2023-10-04 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019108368A Active JP7232128B2 (ja) | 2013-07-22 | 2019-06-11 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2021083925A Pending JP2021121608A (ja) | 2013-07-22 | 2021-05-18 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2022157885A Active JP7362870B2 (ja) | 2013-07-22 | 2022-09-30 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
| JP2023172708A Pending JP2024001149A (ja) | 2013-07-22 | 2023-10-04 | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150024996A1 (enExample) |
| EP (1) | EP3024475B8 (enExample) |
| JP (5) | JP2016525544A (enExample) |
| KR (1) | KR20160033213A (enExample) |
| AU (1) | AU2014293665B2 (enExample) |
| BR (1) | BR112016001544A8 (enExample) |
| CA (1) | CA2919081C (enExample) |
| IL (1) | IL243750A0 (enExample) |
| MX (1) | MX383077B (enExample) |
| WO (1) | WO2015012899A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| KR20160033213A (ko) * | 2013-07-22 | 2016-03-25 | 임프리미스 파마슈티컬스 인코포레이티드 | 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물 |
| US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| JP6682898B2 (ja) * | 2016-02-17 | 2020-04-15 | 富士通株式会社 | 基地局、無線通信システムおよび基地局の処理方法 |
| KR20190109604A (ko) * | 2016-05-06 | 2019-09-25 | 해로우 헬스 인코포레이티드 | 약학적 안과용 조성물 및 그의 제조 방법 |
| DK3541442T3 (da) | 2016-11-16 | 2022-03-14 | Persica Pharmaceuticals Ltd | Antibiotiske formuleringer mod lændesmerter |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| US11484538B2 (en) | 2020-08-26 | 2022-11-01 | Somerset Therapeutics, Llc | Bromfenac, prednisolone, and moxifloxacin compositions and methods |
| US11523987B2 (en) | 2020-08-26 | 2022-12-13 | Somerset Therapeutics, Llc | Trimcinolone and moxifloxacin methods |
| US11382910B2 (en) | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
| EP4260844A1 (en) | 2022-04-11 | 2023-10-18 | Liegner, Jeffery T. | Ophthalmological compositions comprising poloxamer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1192368A (ja) * | 1997-07-23 | 1999-04-06 | Ono Pharmaceut Co Ltd | ベンゾピラン誘導体を主成分とする水性液剤 |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| JP2003176228A (ja) * | 2001-12-11 | 2003-06-24 | Rohto Pharmaceut Co Ltd | 液 剤 |
| US20070049552A1 (en) * | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
| DE602006006308D1 (de) * | 2005-05-10 | 2009-05-28 | Alcon Inc | Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten |
| US20080262415A1 (en) * | 2005-07-18 | 2008-10-23 | Peyman Gholam A | Enhanced wound healing |
| EP2962682B1 (en) * | 2008-12-11 | 2018-03-28 | Massachusetts Institute Of Technology | Method of making a contact lens drug delivery device |
| JP2013508381A (ja) * | 2009-10-21 | 2013-03-07 | オトノミ―,インク. | ポロクサマーを包含する製剤のゲル化温度の調節 |
| WO2011049958A2 (en) * | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
| US20140127269A1 (en) * | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| KR20160033213A (ko) * | 2013-07-22 | 2016-03-25 | 임프리미스 파마슈티컬스 인코포레이티드 | 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물 |
-
2014
- 2014-03-27 KR KR1020167004393A patent/KR20160033213A/ko not_active Ceased
- 2014-03-27 EP EP14721688.1A patent/EP3024475B8/en active Active
- 2014-03-27 AU AU2014293665A patent/AU2014293665B2/en active Active
- 2014-03-27 BR BR112016001544A patent/BR112016001544A8/pt not_active Application Discontinuation
- 2014-03-27 MX MX2016000964A patent/MX383077B/es unknown
- 2014-03-27 JP JP2016529754A patent/JP2016525544A/ja active Pending
- 2014-03-27 CA CA2919081A patent/CA2919081C/en active Active
- 2014-03-27 US US14/227,819 patent/US20150024996A1/en not_active Abandoned
- 2014-03-27 WO PCT/US2014/032026 patent/WO2015012899A1/en not_active Ceased
-
2016
- 2016-01-24 IL IL243750A patent/IL243750A0/en active IP Right Grant
-
2019
- 2019-06-11 JP JP2019108368A patent/JP7232128B2/ja active Active
-
2021
- 2021-05-18 JP JP2021083925A patent/JP2021121608A/ja active Pending
-
2022
- 2022-09-30 JP JP2022157885A patent/JP7362870B2/ja active Active
-
2023
- 2023-10-04 JP JP2023172708A patent/JP2024001149A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525544A5 (enExample) | ||
| US11684570B2 (en) | Pharmaceutical ophthalmic compositions | |
| JP7362870B2 (ja) | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 | |
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| US11510916B2 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| KR20180102069A (ko) | 요법을 위한 응집성 마이크로입자 | |
| CN1829510A (zh) | 抗炎剂的可分散性制剂 | |
| US20160101118A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20160184323A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20160175323A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| JP2017522360A (ja) | 耳垢症の処置のための耳科用製剤 | |
| RU2496501C2 (ru) | Композиции, включающие антибиотик и кортикостероид | |
| JP6694525B2 (ja) | 薬学的眼病用組成物およびそれを製造するための方法 | |
| US20190358344A1 (en) | Mineral coated microparticles for sustained delivery of steroids | |
| WO2023070000A1 (en) | Methods of use and administration of encapsulated cells | |
| CN101969950A (zh) | 用于治疗或控制前段炎症的包含游离的糖皮质激素受体激动剂的组合物 | |
| RU2016101960A (ru) | Способ лечения ушных инфекций после установки тимпаностомической трубки | |
| NZ716208B2 (en) | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent | |
| US20160193144A1 (en) | Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof | |
| CN104334131A (zh) | 眼科药物递送装置和使用方法 | |
| US20160045432A1 (en) | Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof | |
| WO2016024956A1 (en) | Intraocular lens comprising fluoroquinolone and a corticosteroid and methods for fabricating thereof | |
| CA3119363A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| HK1156876B (en) | Composition comprising an antibiotic and a corticosteroid |